Cardio-Oncology

Statins are competitive inhibitors of cholesterol biosynthesis and additional derivatives of the mevalonate pathway. For…

Cancer treatments can lead to cancer therapy–related cardiac dysfunction (CTRCD). Sodium glucose cotransporter-2 inhibitors (SGLT2is)…

The API-CAT trial studied whether among active cancer patients with venous thromboembolism, treatment with a…

Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be…

In the STOP-CA (Statins to Prevent the Cardiotoxicity From Anthracyclines) trial, atorvastatin preserved the left…

Join us as we explore the detection of cancer therapy-related cardiac dysfunction (CTRCD) and its…

Risk stratification strategies for cancer therapeutics-related cardiac dysfunction (CTRCD) rely on serial monitoring by specialized…

Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were…

Older patients with Hodgkin lymphoma (HL) often have comorbid cardiovascular disease; however, the impact of…

Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: a prospective cohort…